Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.

Bibliographic Details
Title: Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
Authors: Short, Nicholas J.1 (AUTHOR) nshort@mdanderson.org, Kantarjian, Hagop1 (AUTHOR), Jabbour, Elias1 (AUTHOR)
Source: Leukemia & Lymphoma. Oct2024, Vol. 65 Issue 10, p1405-1417. 13p.
Subject Terms: *HEMATOPOIETIC stem cell transplantation, *PHILADELPHIA chromosome, *LYMPHOBLASTIC leukemia, *OLDER people, *ACUTE leukemia
Abstract: Blinatumomab and inotuzumab ozogamicin (INO) are both active in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional chemotherapy in this setting. Several prospective clinical trials have explored the use of these agents in adults with newly diagnosed B-cell ALL, with promising outcomes observed in younger and older adults and in both Philadelphia chromosome (Ph)-positive and Ph-negative ALL. These novel regimens result in high rates of deep measurable residual disease (MRD) negativity and may improve survival compared with chemotherapy-only approaches, allowing for less reliance on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). This review discusses novel approaches to integrating INO and/or blinatumomab into frontline ALL regimens, including the potential role of chemotherapy-free regimens in some subgroups. The role of MRD monitoring is also discussed, including how this can inform decisions for consolidative allogeneic HSCT or investigational approaches with CD19 CAR T-cells. [ABSTRACT FROM AUTHOR]
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
Full text is not displayed to guests.
More Details
ISSN:10428194
DOI:10.1080/10428194.2024.2364043
Published in:Leukemia & Lymphoma
Language:English